NEW YORK (GenomeWeb News) – Response Biomedical said today that it has received C$283,756 (US$279,640) from the Canadian government to support its Ramp point-of-care platform.
The funding from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) will be used by Vancouver, British Columbia-based Response Biomedical for a project to improve the Ramp platform and increase the firm's ability to compete in the marketplace.
Response Biomedical did not elaborate on the project, saying only that the goal is to "improve the customer experience" with the platform.
The Ramp system consists of a reader and single-use disposable test cartridges. The Ramp Reader and Ramp 200 reader are portable scanning fluorescence quantitative analysis platforms for near-patient testing.
Clinical tests for the Ramp system are currently available for the early detection of heart attack and congestive hear failure. In the non-clinical arena, Ramp tests exists for the environmental detection of West Nile Virus, as well biodefense applications such as the on-site detection of anthrax, smallpox, ricin, and botulinum toxin.